Your Yourlocation: Home > Industry News: Boehringer tiotropium bromide(136310-93-5) drugs approved by the FDA

Boehringer come from behind, that its chronic obstructive pulmonary disease drugs can go beyond other competitors. The company is awaiting FDA approval for a combination of olodaterol and the LAMA bronchodilator tiotropium bromide(136310-93-5), the latter approved by the company. Boehringer revealed in May that the main phase 3 results showed that the combination underwent a 6-week course of improvement in lung function in terms of beating the placebo and combination of each drug itself.

The FDA has approved Boehringer Ingelheim's new drug delivery inhaler Striverdi Respimat, a daily dose of chronic obstructive pulmonary disease, which the German drugmaker hopes will position itself in the fiercely competitive market for respiratory drugs.

The inhaler, called olodaterol, is a long-acting beta-2 agonist (LABA) that relaxes the airway muscles and prevents lung diseases such as chronic bronchitis and emphysema. The US Food and Drug Administration has approved Boehringer to sell its chronic obstructive pulmonary disease drug, which is the third leading cause of death in the United States, and like other LABA drugs, Striverdi will have a black-box warning warning detailing Risk of death associated with asthma.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved